# The Impact of Compound Danshen Dropping Pills (CDDP) on the Post-myocardial Infarction Ventricular Remodeling

Study · id `cardio:ct-nct05000411` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT05000411](<https://clinicaltrials.gov/study/NCT05000411>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT05000411

Browse, organ or system: Heart  
Browse, condition area: Coronary and vascular disease; Acute care and long-term living  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 268 participants.

## Technical summary

Registry record NCT05000411. Randomized; double masking; primary purpose treatment. Start 2021-08-25 (actual); primary completion 2023-08-25 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; double masking; primary purpose treatment
- Phase: Phase 4
- Enrolled: 268 participants (planned count; ClinicalTrials.gov record NCT05000411, source copy `cardio:ctgov-nct05000411-2023-04-11`, retrieved 2026-10-26)
- Started: 2021-08-25 (actual) (ClinicalTrials.gov record NCT05000411, source copy `cardio:ctgov-nct05000411-2023-04-11`, retrieved 2026-10-26)
- Primary completion: 2023-08-25 (anticipated) (ClinicalTrials.gov record NCT05000411, source copy `cardio:ctgov-nct05000411-2023-04-11`, retrieved 2026-10-26)
- Completion: 2024-03-01 (anticipated) (ClinicalTrials.gov record NCT05000411, source copy `cardio:ctgov-nct05000411-2023-04-11`, retrieved 2026-10-26)
- Countries: China (ClinicalTrials.gov record NCT05000411, source copy `cardio:ctgov-nct05000411-2023-04-11`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "UNKNOWN" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct05000411-2023-04-11`, retrieved 2026-10-26)

## The registry's words

- Brief title: The Impact of Compound Danshen Dropping Pills (CDDP) on the Post-myocardial Infarction Ventricular Remodeling
- Condition: Myocardial Infarction
- Intervention (Drug): Compound Danshen Dropping Pills (CDDP)
- Intervention (Drug): Placebo
- Lead sponsor: The First Affiliated Hospital with Nanjing Medical University
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Heart attack (myocardial infarction) (`cardio:myocardial-infarction`)
- Registry lists this organization as the lead sponsor: The First Affiliated Hospital with Nanjing Medical University (`cardio:org-the-first-affiliated-hospital-with-nanjing-medical-898271`)

## Provenance

Content hash: 6b8c965ef1a227d2e00a01bd00ee8a085f8e36027b5642b1badf2e3bbea9147f
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
